GREAT POINT PARTNERS LLC - Q3 2019 holdings

$1.09 Billion is the total value of GREAT POINT PARTNERS LLC's 43 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 83.3% .

 Value Shares↓ Weighting
IOVA  IOVANCE BIOTHERAPEUTICS, INC$95,747,000
-99.9%
5,260,8030.0%8.80%
-38.6%
ZGNX BuyZOGENIX, INC.$80,080,000
-99.9%
2,000,000
+25.5%
7.36%
-13.0%
ACAD BuyACADIA PHARMACEUTICALS, INC.$78,845,000
-99.8%
2,190,742
+46.0%
7.24%
+62.7%
BOLD BuyAUDENTES THERAPEUTICS, INC.$69,804,000
-99.9%
2,485,000
+29.2%
6.41%
-20.7%
PTCT BuyPTC THERAPEUTICS, INC.$67,640,000
-99.9%
2,000,000
+1.3%
6.21%
-37.0%
ZYME BuyZYMEWORKS INC$61,175,000
-99.7%
2,466,744
+131.8%
5.62%
+116.2%
XLRN BuyACCELERON PHARMA INC$57,475,000
-99.9%
1,454,700
+0.4%
5.28%
-20.1%
MDCO NewThe Medicines Companycall$50,000,0001,000,000
+100.0%
4.59%
KURA BuyKURA ONCOLOGY, INC$46,815,000
-99.9%
3,086,053
+1.3%
4.30%
-35.5%
PEN NewPENUMBRA INC$40,347,000300,000
+100.0%
3.71%
NKTR NewNEKTAR THERAPEUTICS$38,707,0002,125,000
+100.0%
3.56%
ASND NewASCENDIS PHARMA AScall$38,528,000400,000
+100.0%
3.54%
UTHR NewUNITED THERAPEUTICS CORP$37,483,000470,000
+100.0%
3.44%
ASND SellASCENDIS PHARMA ASsponsored adr$28,896,000
-99.9%
300,000
-40.0%
2.65%
-58.5%
MRTX  MIRATI THERAPEUTICS INC$23,373,000
-99.9%
300,0000.0%2.15%
-37.4%
MRTX  Mirati Therapeutics, Inc.put$23,373,000
-99.9%
300,0000.0%2.15%
-37.4%
DXCM NewDEXCOM, INC$22,575,000151,264
+100.0%
2.07%
RTRX BuyRETROPHIN INC$20,167,000
-99.9%
1,740,000
+73.4%
1.85%
-17.2%
TCDA SellTRICIDA, INC.$18,118,000
-100.0%
586,929
-58.8%
1.66%
-73.3%
DERM BuyDERMIRA INC$16,750,000
-99.9%
2,621,333
+68.8%
1.54%
-6.6%
PRTA BuyPROTHENA CORPORATION PLC$16,198,000
-99.9%
2,066,041
+23.3%
1.49%
-24.4%
IONS NewIONIS PHARMACEUTICALS, INC.$16,176,000270,000
+100.0%
1.49%
TNDM NewTANDEM DIABETES CARE, INC.$14,745,000250,000
+100.0%
1.35%
MRTX  Mirati Therapeutics, Inc.call$13,634,000
-99.9%
175,0000.0%1.25%
-37.4%
MNTA BuyMOMENTA PHARMACEUTICALS, INC.$12,960,000
-99.7%
1,000,000
+192.3%
1.19%
+151.6%
GNFT SellGENFIT ADR$11,935,000
-99.9%
685,553
-1.3%
1.10%
-28.0%
ZGNX NewZOGENIX, INC.call$10,010,000250,000
+100.0%
0.92%
ALLK NewALLAKOS, INC.$9,829,000125,000
+100.0%
0.90%
SILK NewSILK ROAD MEDICAL INC$9,823,000301,979
+100.0%
0.90%
MLND  MILLENDO THERAPEUTICS, INC$9,158,000
-99.9%
1,288,0930.0%0.84%
-49.1%
TPTX NewTURNING POINT THERAPEUTICS, INC.$8,356,000222,222
+100.0%
0.77%
MNLO SellMENLO THERAPEUTICS INC.$7,401,000
-99.9%
1,652,013
-4.7%
0.68%
-41.0%
ABEO NewABEONA THERAPEUTICS INC$7,312,0003,235,601
+100.0%
0.67%
ATRA NewATARA BIOTHERAP$7,060,000500,000
+100.0%
0.65%
EXEL NewEXELIXIS, INC$5,477,000309,700
+100.0%
0.50%
AXSM NewAxsome Therapeutics, Inccall$4,048,000200,000
+100.0%
0.37%
IOVA  IOVANCE BIOTHERAPEUTICS, INCcall$3,640,000
-99.9%
200,0000.0%0.33%
-38.6%
PTI  PROTEOSTASIS THERAPEUTICS INC.$2,958,000
-99.9%
3,500,0000.0%0.27%
-28.2%
MYOV NewMYOVANT SCIENCES LTD$1,690,000325,000
+100.0%
0.16%
OPK NewOPKO HEALTH INC$193,00092,140
+100.0%
0.02%
STRM  STREAMLINE HEALTH SOLUTNS, INC$141,000
-99.9%
130,1370.0%0.01%
-40.9%
ZFGN ExitZAFGEN INC.$0-2,211,194
-100.0%
-0.29%
FPRX ExitFIVE PRIME THERAPEUTICS, INC.$0-547,712
-100.0%
-0.37%
OSMT ExitOSMOTICA PHARMACEUTICALS PLC$0-926,933
-100.0%
-0.39%
FOMX ExitFOAMIX PHARMACEUTICALS LTD$0-2,110,071
-100.0%
-0.56%
BHVN ExitBIOHAVEN PHARMACEUTICAL HOLDING CO. LTD.put$0-200,000
-100.0%
-0.97%
ZGNX ExitZOGENIX, INC.put$0-300,000
-100.0%
-1.59%
BHVN ExitBIOHAVEN PHARMACEUTICAL HOLDING CO LTD.$0-350,000
-100.0%
-1.70%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-11-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
STREAMLINE HEALTH SOLUTNS, INC CMN25Q3 20192.5%
IOVANCE BIOTHERAPEUTICS, INC. CMN16Q1 202114.3%
ZOGENIX INC CMN16Q4 20198.8%
PTC THERAPEUTICS, INC. CMN16Q3 20239.9%
EXELIXIS, INC16Q1 20227.5%
SAGE THERAPEUTICS, INC CMN15Q3 202110.8%
CYTOKINETICS INC15Q3 20235.8%
ACADIA PHARMACEUTICALS, INC.14Q1 20218.8%
ACCELERON PHARMA INC CMN14Q2 20208.2%
CONNECTURE INC13Q4 201725.1%

View GREAT POINT PARTNERS LLC's complete holdings history.

Latest significant ownerships (13-D/G)
GREAT POINT PARTNERS LLC Q3 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
89bio, Inc.February 14, 2023700,0001.4%
KalVista Pharmaceuticals, Inc.February 14, 20231,055,8013.1%
Avalo Therapeutics, Inc.February 13, 2023974,6397.1%
InflaRx N.V.Sold outFebruary 14, 202200.0%
ABEONA THERAPEUTICS INC.Sold outFebruary 16, 202100.0%
CONSTELLATION PHARMACEUTICALS INCFebruary 16, 20211,024,8002.2%
GERON CORPFebruary 16, 202112,754,2284.0%
Millendo Therapeutics, Inc.February 16, 2021270,0001.4%
NextCure, Inc.Sold outFebruary 16, 202100.0%
PROTHENA CORP PUBLIC LTD COFebruary 16, 2021977,6472.4%

View GREAT POINT PARTNERS LLC's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G2024-04-08
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View GREAT POINT PARTNERS LLC's complete filings history.

Compare quarters

Export GREAT POINT PARTNERS LLC's holdings